lenalidomide has been researched along with Myeloproliferative-Myelodisplastic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangat, N; Mudireddy, M; Nicolosi, M; Patnaik, MM; Tefferi, A; Vallapureddy, R | 1 |
| Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M | 1 |
2 other study(ies) available for lenalidomide and Myeloproliferative-Myelodisplastic Diseases
| Article | Year |
|---|---|
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Topics: Anemia, Sideroblastic; Humans; Lenalidomide; Myelodysplastic-Myeloproliferative Diseases; Thrombocytosis | 2018 |
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide.
Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nitrosourea Compounds; Skin; Sweet Syndrome; Thalidomide; Thrombocythemia, Essential; Treatment Outcome | 2014 |